SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549
FORM 8-KCURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 21, 2002VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)
(State or other jurisdiction (Commission (I.R.S. Employer incorporation
of Identification Number) File Number) or organization)
1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA94005
(Address of Principal Administrative Offices)
Registrants Telephone Number, Including Area Code: (650) 624-1000
Item 5. Other Events.
On October 21, 2002, VaxGen, Inc. (the "Company") announced that the independent
board that oversees the Company's clinical trials completed the final safety and
conduct review of the Company's Phase III trial in Thailand and once again
concluded that the study was being conducted appropriately and that the
Company's AIDS vaccine candidate appears safe. The independent board also
conducted an interim analysis of efficacy using data from the trial in Thailand
and recommended that the study continue to its planned conclusion in the second
half of 2003.
The press release is filed herewith as Exhibit 99.1 and incorporated herein by
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
EXHIBIT DESCRIPTION 99.1Press Release issued October 21, 2002.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: October 22, 2002 By: /s/ Carter A. Lee
Carter A. Lee
Senior Vice President
Finance & Administration